Hillstream BioPharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HILS research report →
Companywww.hillstreambio.com
Hillstream BioPharma, Inc. , a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors.
- CEO
- Randy D. Milby MBA
- IPO
- 2022
- Employees
- 1
- HQ
- Bridgewater, NJ, US
Price Chart
Valuation
- Market Cap
- $4.17M
- P/E
- -0.61
- P/S
- 0.00
- P/B
- 0.10
- EV/EBITDA
- 0.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -36.93%
- ROIC
- -8.26%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-35,916,250 · -194.45%
- EPS
- $-1.12 · 88.10%
- Op Income
- $-20,106,066
- FCF YoY
- -47.94%
Performance & Tape
- 52W High
- $2.65
- 52W Low
- $0.17
- 50D MA
- $0.25
- 200D MA
- $0.58
- Beta
- 0.00
- Avg Volume
- 684.78K
Get TickerSpark's AI analysis on HILS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 15, 23 | MILBY RANDY | buy | 29,000 |
| Nov 30, 23 | MILBY RANDY | buy | 10,000 |
| Nov 7, 23 | Bui Lynne A. | other | 25,000 |
| Nov 7, 23 | Appajosyula Sireesh | other | 25,000 |
| Nov 7, 23 | Anderson Kelly | other | 50,000 |
| Nov 7, 23 | Mazur Leonard L | other | 25,000 |
| May 9, 23 | Anderson Kelly | other | 0 |
| Jan 1, 23 | MILBY RANDY | other | 515,127 |
| Jan 1, 23 | MILBY RANDY | other | 621,795 |
| Jul 14, 22 | Appajosyula Sireesh | other | 75,757 |
Our HILS Coverage
We haven't published any research on HILS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HILS Report →